# CheckMate 238 (NCT02388906)

> Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02388906
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Melanoma
- Interventions: Ipilimumab; Nivolumab; Placebo matching Ipilimumab; Placebo matching Nivolumab
- Enrollment: 906
- Primary outcome: Recurrence-free Survival (RFS)

## Commentary we found

- Podcasts: 18
- YouTube: 6
- X threads: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=checkmate-238-nct02388906

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02388906", "email": "<work email>"}; the inbox owner confirms by the emailed link.